A Biophysical Model of Cell Adhesion Mediated by Immunoadhesin Drugs and Antibodies by Gutenkunst, Ryan N. et al.
A Biophysical Model of Cell Adhesion Mediated by
Immunoadhesin Drugs and Antibodies
Ryan N. Gutenkunst
1*, Daniel Coombs
2, Toby Starr
3, Michael L. Dustin
3, Byron Goldstein
4
1Department of Molecular and Cellular Biology, University of Arizona, Tucson, Arizona, United States of America, 2Department of Mathematics and Institute of Applied
Mathematics, University of British Columbia, Vancouver, British Columbia, Canada, 3Department of Pathology, New York University School of Medicine and Program in
Molecular Pathogenesis, Skirball Institute of Biomolecular Medicine, New York, New York, United States of America, 4Theoretical Biology and Biophysics Group,
Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America
Abstract
A promising direction in drug development is to exploit the ability of natural killer cells to kill antibody-labeled target cells.
Monoclonal antibodies and drugs designed to elicit this effect typically bind cell-surface epitopes that are overexpressed on
target cells but also present on other cells. Thus it is important to understand adhesion of cells by antibodies and similar
molecules. We present an equilibrium model of such adhesion, incorporating heterogeneity in target cell epitope density,
nonspecific adhesion forces, and epitope immobility. We compare with experiments on the adhesion of Jurkat T cells to
bilayers containing the relevant natural killer cell receptor, with adhesion mediated by the drug alefacept. We show that a
model in which all target cell epitopes are mobile and available is inconsistent with the data, suggesting that more complex
mechanisms are at work. We hypothesize that the immobile epitope fraction may change with cell adhesion, and we find
that such a model is more consistent with the data, although discrepancies remain. We also quantitatively describe the
parameter space in which binding occurs. Our model elaborates substantially on previous work, and our results offer
guidance for the refinement of therapeutic immunoadhesins. Furthermore, our comparison with data from Jurkat T cells
also points toward mechanisms relating epitope immobility to cell adhesion.
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Introduction
When a pathogen elicits a humoral immune response,
antibodies are produced that bind to specific epitopes on the
surface of the pathogen. Once antibodies have bound to the
pathogen, it is labeled as foreign, and various processes can follow
that lead to its elimination. One such process, antibody-dependent
cell-mediated cytotoxicity (ADCC), involves natural killer (NK)
cells binding through their FccRIIIa (CD16a) receptors to IgG
antibodies decorating the pathogen (reviewed in [1]). The coupling
of an NK cell to a target cell brings parts of the surfaces of the two
cells into proximity, within roughly 100A ˚. In the region of tight
contact where antibodies form bridges between the two cells, both
the density of epitopes on the target cell and the density of Fc
receptors on the NK cell are locally increased. When the density of
Fc receptors in the contact region on the NK cell is sufficiently
high, a cellular response is triggered, the end point of which is the
release of lytic granules containing perforin and granzymes, whose
combined effect results in the killing of the target cell [2–4].
Depending on the nature of the epitope and type of cell, the
aggregation of epitopes on the target cell may also trigger cellular
responses [5,6].
Monoclonal antibodies and antibody-like fusion proteins have
been developed to take advantage of ADCC. These drugs target
naturally occurring proteins that are overexpressed on tumor cells
and on populations of cells that drive autoimmune responses [1,7–
10]. Unfortunately, these drugs will also target a subset of healthy
cells because the target is a naturally occurring protein. An obvious
question, which we address in this paper, is what properties of a
drug, the cells that express the target protein, and the NK cells
determine a drug’s ability to discriminate between pathogenic and
healthy cells? A second question that we consider, that is closely
related to the first, is what determines the range of drug
concentrations over which a drug will couple target cells to NK
cells? These drugs, either in animal models or patients, must
compete for Fc receptors on NK cells with endogenous IgG [11].
We therefore also examine how background IgG influences the
range of drug concentrations over which adhesion occurs.
We previously presented an equilibrium model that describes
the coupling via a monoclonal antibody (or an appropriate fusion
protein) of identical target cells to a surface expressing mobile Fc
receptors [12]. Here, we significantly extend our model to allow
for a target cell population with a distribution of surface epitope
density. This allows us to analyze experiments where the
percentage of bound target cells is determined as a function of
the ligand concentration. We also extend the model to admit the
possibility of nonspecific adhesion between target cells and the
surface. Our extended model also addresses the possibility that
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in which the immobile fraction depends on epitope cross-linking or
the size of the contact region. These cases model some potential
target cell responses to adhesion.
To test predictions of the model, we use an experimental system
consisting of a planar bilayer containing mobile FccRIIIb (CD16b)
receptors, Jurkat T cells expressing the cell-adhesion molecule
CD2, and the drug alefacept that binds the target cell to the
bilayer [12]. FccRIIIb differs from FccRIIIa, the receptor on NK
cells, in that it lacks a transmembrane region and a cytoplasmic tail
and it anchors to membranes via glycosolphosphatidylinositol
[13]. Further, the extracellular domains of the two receptors differ
by six amino acids, which probably accounts for FccRIIIb having
a lower affinity for IgG than FccRIIIa [13,14]. Alefacept is a
recombinant fusion protein that has an antibody-like architecture
where the Fab binding sites have been replaced by the natural
ligand for CD2, the extracellular domain of CD58 [15,16], and
fused to the human IgG1 hinge, CH2, and CH3 domains [2]. It is
used in the treatment of psoriasis, an autoimmune disease.
Alefacept reduces the number of circulating memory-effector T
cells in treated patients and mediates ADCC in vitro [2,17–20].
Alefacept is an example of an immunoadhesin, which is a
molecule that uses the basic framework of an IgG antibody, but
replaces the Fab binding sites with the ectodomain of an adhesion
molecule. Immunoadhesins have the specificity of an adhesion
molecule as well as some properties of an antibody, such as the
ability to bind to Fc receptors and a long half-life in plasma that is
similar to IgG [21,22]. An interesting property of alefacept is that
it mediates adhesion and killing of target cells by NK cells at nM
concentrations [12], even though both the binding of IgG to
FccRIIIa and the binding of CD58 to CD2 [23] are low affinity,
with dissociation constants in the mM range. The model we
present will show how the range of drug concentrations over which
adhesion occurs depends on these equilibrium constants as well as
the other parameters of the system.
Methods
We consider a population of target cells expressing a particular
epitope, with some fraction of the epitopes freely diffusing in the
target cell membrane and the remainder immobile (i.e., fixed in
position on the membrane). Additionally, we consider a bilayer
with mobile receptors diffusing on its surface and a ligand capable
of simultaneously binding both the epitope and the receptor
through different sites. The ligand is either a monoclonal antibody
or an immunoadhesin; its Fab arms bind monovalently or
divalently to the epitope on the target cells, and its Fc leg binds
monovalently to the receptor on the bilayer. At some ligand
concentration a contact region forms between the cell and the
bilayer; its area is an increasing function of the number of ligand-
mediated bridging bonds that form. The ligand also competes for
receptor binding with nonspecific antibodies that cannot form
bridging bonds.
Concentrations and equilibrium constants
The potential reactions among mobile and immobile epitopes,
ligand, receptor, and nonspecific antibody are illustrated in Fig. 1.
Each molecular complex is labeled by our mathematical notation
for its surface concentration. All species except those involving a
bridging bond (b10, b20, b11, and b01) exist both inside and outside
the contact region, and the subscript ‘in’ denotes species inside the
contact region. Detailed balance places six constraints on the
equilibrium constants, which we use to eliminate the underlined
constants in Fig. 1 (Text S1). To find the equilibrium state of this
system for any given bulk ligand concentration L, we solve five
algebraic equations for five unknowns: the free immobile epitope
concentrations outside i and inside iin the contact region, the free
mobile epitope e and receptor r concentrations outside the contact
region, and the fraction of the target cell surface d comprising the
contact region. To make our analysis tractable, we make several
simplifying assumptions regarding the equilibrium configuration of
receptors and epitopes.
Our first assumption is that the equilibrium constants for
reactions involving immobile epitopes are identical to the
corresponding constants involving mobile epitopes: KI~KE,
KHE~Kx, Kb01~Kb10:Kb1, and KFH~Kb20:Kb2. Making this
assumption substantially reduces the number of unknown
parameters. We expect that this assumption leads to negligible
error, because the relevant physical interactions are identical for
mobile and immobile epitopes. In particular, because they are
equilibrium constants, these parameters are not altered by the
difference in diffusivity between mobile and immobile epitopes.
Our second assumption is that the typical distance between
immobile epitopes on the target cell is large compared with the
span of the two arms of the ligand, so that the ligand cannot cross-
link immobile epitopes. Thus we do not consider complexes
containing more than one immobile receptor. Given a CD2
surface density r, and assuming that the CD2 epitopes are
uniformly distributed, the probability P(dva) that an epitope’s
nearest neighbor is a distance a away or closer is [24]
P(dva)~1{e{pra2
: ð1Þ
As detailed later, each T-cell contains of order 64,000 CD2
epitopes, over a surface area of roughly 800mm2, yielding a density
of r~80mm{2. Given this density, the probability that an
epitope’s nearest neighbor is closer than the span of roughly
10 nm [25] between epitope binding arms of an antibody-like
Figure 1. Model reaction network. All molecular species and
reactions are labeled. All reactions are reversible; the arrow in the figure
denotes the forward direction for defining the equilibrium constant,
which labels the arrow. Underlined rate constants are eliminated using
detailed balance.
doi:10.1371/journal.pone.0019701.g001
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cross-links between immobile epitopes will indeed be rare, because
the density of immobile epitopes is even lower than the total
epitope surface density.
Our third assumption relates the free mobile epitope and
receptor concentrations inside and outside the contact region.
In earlier experiments, fluorescently labeled CD48 (Cy5-CD48)
was coupled to the bilayer, and it was observed that the
fluorescence from CD48 was reduced in the contact region to
approximately 75% of its value outside the contact region [12].
This suggests that the contact region introduces steric
hindrance and partitions mobile surface proteins between the
inside and outside of the contact region. We assume that at
equilibrium ein~sEe and rin~sRr,w h e r eein and rin are
respectively the free epitope and free receptor concentrations
inside the contact region and sE and sR are equilibrium
partition coefficients. The partition coefficients for FccRIIIb
and CD2 have not been determined; we assume they behave
similarly to CD48 because they are of similar size, so we take
sR~sE~0:75. In Figure S1A we explore the sensitivity of our
results to this assumption.
Using the law of mass action and these additional assumptions,
we can write the equilibrium concentration of all bound complexes
in terms of the free epitope, receptor, ligand, and nonspecific
antibody concentrations. For example, the concentration hin of
complexes inside the contact region consisting of a ligand cross-
linking a mobile and an immobile epitope is
hin~Kxiine1in~2KxKELiinein~2KxKELsEiine: ð2Þ
The factor of 2 in calculating the concentration e1in of complexes
between a ligand and mobile epitope arises because KE is a single-
site equilibrium constant, and there are two potential binding sites
on the ligand. Similarly, the concentration b11 of bridging
complexes involving a receptor, a mobile epitope, and an
immobile epitope is
b11~Kb2hinrin~Kb2hinsRr: ð3Þ
The full system of equilibrium relations is given in Text S1.
Given our assumptions, in the limit that target cells are
sparse, the equilibrium state will depend on six equilibrium
constants (KR, KG, KE, Kx, Kb1,a n dKb2); two partition
coefficients (sE and sR); the total receptor rT,e p i t o p eeT,l i g a n d
LT, and nonspecific antibody GT concentrations; and the
epitope immobile fraction g.A d d i t i o n a l l y ,t w op a r a m e t e r sb and
Anon (detailed later) relate the area of the contact region to the
number of bridging bonds. Finally, to connect our model with
the data, we require the surface area Acell of the Jurkat T cells
studied. In our analyses, a number of these parameters were
held fixed (Table 1).
Most of our fixed parameter values come directly from
measurements; an exception is Kx, the cross-linking constant for
alefacept binding. To estimate Kx, we equate the measured
apparent dissociation constant KD for alefacept adhering to T cells
to the inverse of the initial slope m0 of a Scatchard plot for a
bivalent ligand binding to a monovalent receptor [26]:
m0~{
2KE(1zKxeT)
2
1zKxeT=2
~{
1
KD
: ð4Þ
Using the mean CD2 count measured for our cells of 6:4|104
and Acell to calculate eT, along with KD~0:1mM [12] yields the
value for Kx in Table 1. With the exception of the fit parameter
Kb2, our results are insensitive to the precise value of Kx (Figure
S1B).
Conservation laws
In the experiments we consider, there is negligible depletion of
ligand, so the free ligand concentration is well approximated by
the total ligand concentration (L&LT). Similarly, in the
experiments with nonspecific antibody, the antibody is negligibly
depleted, so G&GT. Conservation of epitopes and receptors,
however, introduces additional constraints on the concentrations
of various complexes.
In our model, there are three classes of epitopes: mobile
epitopes, immobile epitopes outside the contact region, and
immobile epitopes inside the contact region. We assume that the
concentrations of all species have reached equilibrium. For mobile
epitopes, we have
Acell(1{g)eT~(Acell{A)(eze1z2e2zh)z
A(b10z2b20zb11zeinze1inz2e2inzhin),
ð5Þ
where eT is the average epitope density on the cell surface, equal
to the total epitope count ET divided by the cell area Acell,a n d
A is the area of the contact region. This equation expresses the
fact that the total number of mobile epitopes (left-hand side)
must be equal to the total number in complexes outside and
inside the contact region (right-hand side). In terms of the
fraction d of the cell surface in the contact region, the above
conservation law is
(1{g)eT~(1{d)(eze1z2e2zh)z
d(b10z2b20zb11zeinze1inz2e2inzhin):
ð6Þ
Similarly, for immobile epitopes outside the contact region we
have
geT~izi1zh, ð7Þ
and for immobile epitopes inside the contact region we have
geT~iinzi1inzhinzb01zb11: ð8Þ
In our analyses, we consider fits with no immobile epitopes, a
constant immobile fraction g, and a varying immobile fraction g
that is a function of either d or the fraction k of target cell epitopes
that are cross-linked by ligand:
Table 1. Fixed parameter values.
parameter value reference
KR 1:0mM{1 [35–37]
KE 0:67mM{1 [16]
Kx 4:5|10{2mm2 this work
sE 0.75 [12]
sR 0.75 [12]
Acell 800mm2 [12]
doi:10.1371/journal.pone.0019701.t001
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2d(e2inzb20zhinzb11)z2(1{d)(e2zh)
eT
: ð9Þ
For the varying g cases, we consider a linear dependence of g on d
or k:
g~0:13zsdd,or ð10Þ
g~0:13zskk: ð11Þ
Here 0.13 is the experimentally observed immobile epitope
fraction in the absence of ligand [12].
For receptors in the bilayer, we have
AblrT~A(rinzr1inzrGinzb10zb20zb01zb11)z
(Abl{A)(rzr1zrG),
ð12Þ
where Abl is the total area of the bilayer divided by the number of
adhered cells. Dividing by Acell and rearranging yields
rT~ad(rinzr1inzrGinzb10zb20zb01zb11)z
(1{ad)(rzr1zrG),
ð13Þ
where a~Acell=Abl. In the experiments we analyze, for all ligand
concentrations the adhered cells are sparsely distributed over the
bilayer, so we take a~0. In this case, the free receptor
concentration r is simply
r~
rT
1zKRLzKGG
: ð14Þ
Contact region growth law
Bell, Dembo, and Bongrand argued [27] that the bridging bond
density between two adhered cells is determined by a constant
repulsive pressure arising from electrostatic repulsion caused by
negative charges associated with cell surfaces and steric stabiliza-
tion effects. The steric effects arise because cell membranes are
coated by a hydrated layer of long-chain polymers (glycocalyces)
that must compress as cells are brought together and water is
squeezed out of the contact region. Together with the assumption
that cells are easily deformed, this argument implies that the area
of the contact region grows linearly with the number of bridging
bonds.
Although we expect the repulsion between our target cells and
bilayer to be smaller than that between two cells, we expect the
repulsive forces to be of similar origin. Moreover, in our
experiments the small contact regions observed cause only small
cellular deformations, and our target Jurkat T cells are
substantially easier to deform than some other cell types, such as
neutrophils and HL60 cells [28]. However, a recent study of the
binding of Jurkat T cells to bilayers containing the natural CD2
ligand CD58 observed that the average contact area did not go to
zero as the average number of bridging bonds went to zero [29],
and a similar effect may be present in our data. To allow for this
possibility, we include a nonspecific adhesion area Anon into our
contact area growth law, so that the total contact area A is equal to
the the nonspecific contribution Anon plus a specific contribution
proportional to the total number of bridging bonds:
A~Anonz
A(b10zb20zb01zb11)
b
: ð15Þ
Dividing both sides by Acell, we obtain
d~Anon=Acellz
b10zb20zb01zb11
b
d: ð16Þ
The parameter b is the bridging bond density required to balance
the repulsive force per unit area between the cell and the bilayer.
Solving the five constraint equations (Eq. 6, 7, 8, 13, and 16) for
the five unknowns (e, i, iin, r, and d) allows us to calculate the area
of the contact region for a cell with a specified epitope density eT
given the ligand concentration L.
For physical (i.e., non-negative) concentrations of bridging
bonds, Eq. 16 strictly constrains the contact area A to be greater
than the nonspecific contact area Anon. In our data, we observe
that not all cells adhere at low and high ligand concentrations,
corresponding to some cells with A~0. This suggests that
nonspecific forces do not help cells initiate adhesion, but rather
act to increase the contact area after specific drug-mediated
interactions have created contact. Thus when calculating whether
or not a cell with a specific epitope density will adhere, we take
Anon~0. Then, for a fixed epitope density, adhesion occurs over a
range of soluble ligand concentrations: L{ƒLƒLz. Similarly,
for a fixed ligand concentration, adhesion occurs only above a
minimal epitope density eTmin. We calculate this minimal density
by solving for d~0 with Anon~0. We expect that taking d~0
rather than setting it equal to some minimal value introduces
negligible error in our estimates of L{, Lz, and eTmin. In our
experiments adhesion was determined in the absence of flow,
based on whether there was accumulation of the receptor CD58 in
the contact area. Even in the presence of weak flows, estimates
suggest that few bonds, and thus small contact areas, are needed to
initiate adhesion [30,31].
We solve the constraint equations and perform all numerics
using the Python library SciPy [32]. Uncertainties on fit
parameters are calculated via bootstrapping, with 100 bootstrap
data sets for each model.
Heterogeneous density of epitopes on target cells
We now consider a target cell population with a normalized
distribution f(eT) of epitope densities. For a given ligand
concentration, if eTmin is the minimum epitope density at which
adhesion will occur, the fraction of cells bound to the bilayer is
ð?
eTmin
f(eT)deT, ð17Þ
and the average area of the contact region is
vAw~Acellvdw~
ð?
eTmin
d(eT)f(eT)deT
ð?
eTmin
f(eT)deT
: ð18Þ
We would like to use a continuous distribution f(eT) in our
model that is flexible enough to approximate a wide range of
epitope distributions and is relatively simple to work with. Of the
Model of Immunoadhesin-Mediated Cell Adhesion
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eT§0, the Weibull distribution fits our needs. The Weibull
distribution has density
f(eT;c,k,l)~
k
l
(
eT{c
l
)
k{1e
{(
eT{c
l
)
k
ifeTwc
0i f eTƒc:
0
B @ ð19Þ
In our fits, we fix the location parameter c to zero. The parameter
k is the Weibull shape parameter. For kv2:6, f(eT) is skewed to
the right, for 2:6vkv3:7 it is essentially unskewed and looks like
a normal distribution, and for kw3:7 it is skewed to the left. For
k~1 and c~0, the Weibull distribution reduces to the
exponential distribution. The mean of the Weibull distribution is
given by lC(1z1=k)zc, where C denotes the Gamma function.
We report k and mean total epitope count vETw, because the
total epitope count is most directly connected with experimental
measurements. From k and vETw, l can be calculated by
inverting the formula for the mean of the Weibull distribution and
dividing by Acell.
Fig. 2 shows the distribution of expression of CD2 on the
surfaces of a population of Jurkat T cells (the target cells in our
study) as determined by flow cytometry. This distribution serves as
a baseline to judge the distributions arising from our model fits.
These measurements were performed on a Becton Dickinson
FacsCaliber. Fluorescein isothiocyanate (FITC) labeling of anti-
bodies and the determination of the fluoresceine:protein ratio was
determined using absorption spectroscopy [33]. Calibration was
performed using FITC standard beads obtained from Bangs
Laboratories (Fishers, IN). Antibody-stained cells were washed
twice prior to analysis.
Numerical solution
In general, calculating d involves numerically solving a system of
five algebraic equations (Eq. 6, 7, 8, 13, and 16). To find the the
bounding ligand (L{ and Lz) and epitope (eTmin) concentrations
for adhesion, we employ numerical root-finding for d~0 with
Anon~0, and we calculate vdw by explicit numerical integration
of d(eT) over the distribution f(eT) from eTmin to infinity. In some
special cases, additional simplifications are possible that dramat-
ically reduce computational difficulty.
When all epitopes are mobile (g~0), there is no depletion of
bilayer receptors (a~0), and there are no nonspecific forces
(Anon~0), the model simplifies substantially to a system of three
equations for e, r, and d. In this case, we can derive polynomial
equations for the bounding ligand concentrations L{ and Lz and
epitope density eTmin for adhesion. Setting d~0 in Eq. 6, 13, and
16 and substituting our expressions for equilibrium species
concentrations (such as Eq. 2) yields a system of three equations
for the unknowns e, r, and L. For a fixed epitope density eT, this
system can be reduced to a single cubic equation in L, which is
given in Text S1. This cubic equation may have either two positive
roots (L{ and Lz) or no positive roots (no adhesion irrespective of
L). Similarly, for a fixed ligand concentration L, the system of
three equations can be reduced to a quadratic equation for eT, the
larger root of which is eTmin (Text S1). Additionally, in this special
case, we can show that vdw~d(veTw), where veTw is the
average epitope density of adhered cells (Text S1). This saves us
from having to numerically integrate over f(eT).
When gw0, direct solution of our system of five constraint
equations will give non-physical results for those cases in which the
immobile epitopes themselves are dense enough to drive adhesion.
Because the immobile epitope density is assumed constant over the
cell surface, this case results in a divergent contact area d,a s
demonstrated in Figure S2. In our application, this phenomenon
only occurs at very high total epitope densities eT, so it makes only
a small contribution in our typical integrations over f(eT), but we
must handle it carefully to avoid numerical difficulties. When the
contact area is divergent, Eq. 16 implies that the total
concentration of bridging bonds must be equal to b. Because it
is the immobile epitopes that are causing this divergence, the
bridging bonds are dominated by b01; therefore, the value of g
which leads to this divergence, gdiv, can be found by solving our
conservation equation for immobile epitopes inside the contact
region (Eq. 8) with b01~b, yielding
gdiv~b
1z2KIL(1zKb1rin)
2Kb1KILeTrin
: ð20Þ
When gwgdiv, we set d~0:5, consistent with a cell completely
flattened against the surface. Similarly, we set d~0:5 whenever
direct solution of the equations would yield a larger value for d.
Altering this maximum value of d has minor influence on our
results, because in our experiments the vast majority of cells have
only a small fraction of their area adhered.
When we consider the immobile fraction to be a function of
crosslinked epitopes or of the contact area, then Eq. 10 or 11
represents an additional constraint to our previous five, to account
for the additional free variable g. There may be multiple self-
consistent solutions of our expanded system of six constraint
equations (Figure S2). Physically, we expect the cell to adopt the
solution corresponding to smaller g, as the cell begins in a state
with minimal epitope immobility. In our calculations we always
adopt the smallest possible solution, by beginning our root-finding
from small d.
Results
Experiments were previously performed to characterize alefa-
cept-mediated bridging of CD2 epitopes on Jurkat T-cells to
fluorescently-labeled FccRIIIb receptors on supported bilayers
[12]. The alefacept concentration L was varied from 0.001 to
100mM, and the fraction of cells bound to the bilayer, the average
size of the contact area, and the average number of bonds in the
contact area were determined. These types of measurements were
made at two different FccRIIIb densities rT on the bilayer: 1200
and 625mm{2. We fit several models of increasing complexity to
this data. As seen in Fig. 3A, it was not obvious from our data
whether the average contact area goes to zero as the average
number of bridging bonds goes to zero, so our fits included
Figure 2. Distribution of CD2 epitope count on Jurkat T cells.
Values were determined by flow cytometry.
doi:10.1371/journal.pone.0019701.g002
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considered the requirements for alefacept-mediated T-cell adhe-
sion, deriving compact expressions for the limiting alefacept
concentrations. Finally, we considered the effect of background
nonspecific IgG on adhesion.
Fit of fully mobile model
We first considered an adhesion model with free diffusion of all
FccRIIIb receptors on the bilayer and all CD2 epitopes on the T
cell. Simultaneous nonlinear least-squares fits of this model to the
data are shown by the solid lines in Fig. 3B. We weighted the
experiments so that both the bond and contact area data went
between zero and one, and we fit six parameters: the bridging bond
density b, the equilibrium constants Kb1 and Kb2, the nonspecific
contact area Anon, and the Weibull distribution parameters k and l.
Table 2 lists the best-fit values of the free parameters along with
95% confidence intervals. Note that the best-fit value of the
nonspecific contact area Anon is 0. The best-fit value for the average
number of epitopes per cell vETw is roughly 5,200. This is much
smaller than the average value of 64,000 determined by direct
numerical integration of the distribution obtained from flow
cytometry (Fig. 2). A reasonable fit could not be obtained when
the distribution of epitopes per cell was taken directly from the flow
cytometry data, because the model always dramatically overesti-
mated the contact area and number of bridging bonds. Note that
previous experiments [12] on Jurkat T cells showed that, on
average, each cell could bind up to 20,000 alefacept molecules. This
suggests that at least 20,000 and up to 40,000 CD2 epitopes were
available for alefacept binding; both values are substantially larger
than the best-fit vETw from this model.
One counter-intuitive property of the fits is that at high and low
ligand concentrations it appears as if there is a slow decline in the
average contact area and number of bridging bonds long after the
number of bound cells has gone to zero. In these cases, the average
contact area is being calculated over the miniscule fraction of cells
that are adhered. For example, with rT~1200mm{2,a t
L~10{4mM, an average of 125 bonds per adhered cell is
predicted, but this involves only a fraction 10{11 of the total cells.
In the experiments, only a few hundred cells were sampled per
data point, and the tails of the Weibull distribution may be a poor
description of the cell population. Whether the Weibull distribu-
tion is a reasonable description of the epitope density on a target
cell population in vivo is an open question, so we have also
considered a lognormal distribution. Although it can fit the flow
cytometry data in Fig. 2 well, when it is used to analyze the data in
Fig. 3, it predicts that as the ligand concentration decreases, the
average contact area and number of bridging bonds go through
minima and then rise, yielding a very poor fit to this data (Figure
S3). Thus, for the lognormal distribution (and possibly other
distributions) the average number of bonds in the contact region
can increase as the ligand concentration goes to zero.
This model with freely diffusing CD2 epitopes dramatically
underestimates the amount of CD2 present on the T cells.
Therefore we considered more complex models incorporating
immobile CD2 epitopes in the following section.
Fit of models with epitope immobility
Prior experiments on Jurkat T cells found that 13% of CD2
epitopes were immobile in the absence of ligand [12]. Further-
more, cell stimulation in T cells may increase CD2 immobility
[34]. Thus we extended our mathematical model to include
potential CD2 epitope immobility and fit several such models to
the data.
We first considered a model in which the immobile epitope
fraction g was a fit constant. In this case, the best-fit value of g was
found to be zero, yielding an identical fit to the fully mobile case.
This motivated us to consider models in which the immobile
fraction was a function of the fraction k of epitopes cross-linked by
ligand or the fractional area d of the specific contact region.
When we fit a model in which the immobile fraction was a
linear function of k (restricting our search to slopes §0), the best-
fit value for the slope of that function was 0, yielding a constant
Figure 3. Adhesion data and model fits. A: Experimental data on average bridging bond count versus average contact area. We plot the model
with Anon~0 and b~204mm{2 (line). B: Fits to contact area, bridging bond, and fraction-adhered data for the best-fit model with all T-cell epitopes
mobile (blue lines) and the best-fit model with epitope immobility g a linear function of the contact area d (red lines).
doi:10.1371/journal.pone.0019701.g003
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worse than the completely mobile model.
The red curves in Fig. 3B show the results from a fit with the
immobile fraction a linear function of the specific contact area d.
In this case, the fit is somewhat improved, and the best-fit estimate
of total epitope count per cell is driven upward to roughly 17,000.
This estimate of vETw is still only about a third of the value
inferred from the flow cytometry data, but it is much closer than
the other models. The best-fit function for g is g~0:13z23d,s o
the immobile fraction increases very rapidly with cell adhesion.
Note that in our data, the largest average specific contact area seen
is roughly 12mm2=Acell~0:015 so that only small values of d are
typically explored, and adding higher-order terms to g(d) yields
negligible improvement in the fit.
Requirements for adhesion
For drug design, an important consideration is what combina-
tions of ligand concentration and target cell epitope count will yield
adhesion. The curves in Fig. 4A separate the region where more
than 50% of cells are adhered (inside each curve) from the region
where less than 50% are adhered for three different scenarios. The
outermost blue curve is the predicted separation curve for the
parameters obtained from the fit with all receptors mobile (that
shown by the blue lines in Fig. 3B). From this curve we can see that
the minimal ligand concentration for adhesion L{ is inversely
proportionaltothesquareoftheepitopedensity:thebottomportion
of the curve has a slope of approximately negative two.
From the complete set of equations for the model with g~0,
a~0, and Anon~0, we can obtain simple approximations for L{
and Lz for a fixed target cell epitope density eT:
L{&
b
e2
TKEKb2KxrTs2
EsR
ð21Þ
and
Lz&
eTKb1rTsEsR
bKR
: ð22Þ
To approximate L{, we assumed that, at the lowest ligand
concentrations that mediate adhesion, all bridging bonds arise from
epitopes bound bivalently (so Kb1~0). For the Lz approximation,
we assumed that, at the highest ligand concentrations that mediate
adhesion, all ligands bound to epitopes are bound singly (so
Kx~Kb2~0). As seen in Fig. 4A, Eq. 21 and 22 closely predict the
ligand concentration of 50% adhesion, when we replace eT by the
average epitope density. Our approximate expression for L{
suggests that ligands similar to alefacept can achieve considerable
selectivity in epitope density on adhered cells, because L{ falls with
the square of the epitope density. Further, because the ligand-
epitope cross-linking constant Kx is proportional to the ligand-
epitope binding constant KE, Eq. 21 implies that L{ falls inversely
with the square of KE, suggesting that a good strategy for lowering
L{ is to develop ligands with higher KE values.
Table 2. Fit results (best-fit values and 95% confidence intervals).
model x2 b (mm{2) Kb1 (mm2) Kb2 (mm2) Anon (mm2) gconst sk,sd k vETw (|103)
g~0 1.190 204 0.6 41 0 1.5 5.2
176–222 0.2–1.6 22–91 0–0.6 .4–1.7 3.8–6.7
g~gconst 1.190 204 0.6 43 0 0 1.5 5.2
180–217 0.3–1.3 23–87 0–0.04 0–0.18 1.4–1.7 4.2–6.9
g~0:13zskk 1.203 201 0.5 36 0 0 1.6 6.1
179–218 0.4–1.3 22–82 0–0.05 0–0.04 1.4–1.8 4.6–7.1
g~0:13zsdd 0.961 203 0.4 4.2 0 23 1.2 17
176–224 0.2–0.7 1.8–13.1 0–0.8 15–28 1.1–1.4 10–27
doi:10.1371/journal.pone.0019701.t002
Figure 4. Adhesion model predictions. A: Curves shown enclose the region of greater than 50% cell adhesion for the best-fit all-mobile model
(blue), the best-fit model with g(d) (red), the g(d) model with 9mM of nonspecific IgG (black), and the g(d) model with ligand-epitope binding
constants KE and Kx each divided by 10 and no nonspecific IgG (green). The thin solid lines show our approximations for the bounding ligand
concentrations L{ and Lz. B: Experimental data on the inhibition of adhesion by nonspecific IgG (open circles) compared with predictions from our
model with the immobile epitope fraction a function of the contact area. The solid line is from the best-fit model, and the dashed lines denote 95%
confidence intervals from our bootstrap parameter uncertainties. Inset plots the same data and prediction on a logarithmic scale.
doi:10.1371/journal.pone.0019701.g004
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best-fit model in which the immobile fraction g is a linear function
of the contact area d. Again, the minimal ligand concentration for
adhesion falls as the square of the epitope density. Our expressions
for L{ and Lz (Eq. 21 and 22) are no longer good
approximations in this case, but the dependence of L{ on the
ligand-epitope binding constants KE and Kx is the same. This is
illustrated by the green curve that bounds the region of adhesion
for the same model and parameters, with the exception that KE
and Kx have been divided by 10. As expected from Eq. 21, the
minimal ligand concentration for adhesion has increased by a
factor of 100.
Adhesion inhibition by nonspecific IgG
In vivo, alefacept-mediated adhesion depends not only on the
concentration of alefacept and the density of CD2 on the T cells,
but also on the presence of background nonspecific IgG, which
can bind the NK cell receptor and inhibit adhesion. To test the
sensitivity of adhesion to background concentrations of nonspecific
IgG, the percentage of cells bound to the bilayer was determined
in the presence of 0:5mM of the ligand (alefacept) and differing
concentrations G of purified human IgG, with a receptor
concentration in the bilayer of 450mm{2 [12]. Nonspecific IgG
inhibits cell adhesion by reducing the free receptor concentration
(Eq. 14). To have a substantial effect, KGG must be greater than 1,
where in these experiments the IgG binding constant KG is equal
to our KR. In Fig. 4B, an inhibition of 50% is achieved with an
IgG concentration of about 7mM, suggesting that KR§
0:15mM{1, consistent with the value of KR~1:0mM{1 [35–37]
we took in our fits. Fig. 4B shows good agreement between our
predicted inhibition curve using the best-fit parameters for the g(d)
model and the experimental data, providing further validation of
our model.
The effect of nonspecific IgG can be interpreted as reducing both
the effective total receptor concentration and the effective ligand-
receptor binding equilibrium constant. In the equation for the free
receptor concentration (Eq. 14), if we replace rT by an effective
r
0
T~rT=(1zKGG) and replace KR by an effective K
0
R~
KR=(1zKGG),w eo b t a i nr~rT=(1zKRLzKGG)~r
0
T=(1z
K
0
RL). Because the model depends on rT and KR only through r,
changing variables to an effective r
0
T and K
0
R exactly mimics the effect
of nonspecific IgG. This allows us to apply our approximations (Eq.
21 and 22) for the minimal L{ and maximal Lz ligand
concentrations necessary for substantial adhesion to the case with
competing nonspecific IgG. In our expression for L{ (Eq. 21), rT
appears only in the denominator, so the effect of adding non-specific
IgG to the system is to increase L{ by a factor of 1zKGG.I no u r
expression for Lz (Eq. 22), rT appears in the numerator and KR
appears in the denominator, so the effects cancel, and Lz is
unchanged. These changes in L{ and Lz are illustrated by the black
curve in Figure 4A, which encloses the region of greater than 50%
adhesion when the concentration of IgG is 9mM,s ot h a t
1zKGG~10, for our best-fit model in which the immobile fraction
g is a linear function of the contact area d.
Discussion
We have developed an equilibrium model for the ligand-
mediated adhesion of cells to surfaces. Our model incorporates
immobility of epitopes, potential nonspecific adhesion forces,
heterogeneities in target cell epitope density, and the possibility
that ligand binding or adhesion alters the immobile epitope
fraction. We have applied our model to experiments on the
alefacept-mediated adhesion of Jurkat T cells expressing CD2 to
bilayer membranes containing the receptor FccRIIIb, a close
relative of the relevant receptor on natural killer cells. We find that
our data are best described by a model in which the immobile
epitope fraction is a function of the contact area between the target
cell and bilayer. Nevertheless, our best-fit model still underesti-
mates the epitope density on Jurkat T cells, perhaps indicating that
other factors influence CD2-mediated adhesion and opening a
direction for future study.
Our results also suggest general guidelines for the design of
immuno-adhesive molecules. We find that for bivalent ligands the
minimal ligand concentration L{ required for adhesion is
inversely related to the square of the target cell epitope density,
illustrating the potential selectivity of these ligands. We also show
that L{ is a quadratic function of the epitope-ligand binding
constants, even for our more complex models, suggesting that
tuning this interaction may be a fruitful route for drug design.
It is instructive to compare our fit parameters with those from
previous investigations of Jurkat T cell adhesion. A previous
analysis of adhesion to bilayers containing the natural CD2
binding partner CD58 found a nonspecific contact area of 7:6mm2
[29]. We, however, find that the nonspecific contact area is driven
to zero in all our fits. That previous analysis found the density of
bridging bonds b at equilibrium to be approximately 1000mm{2,
substantially greater than our value of 200mm{2. This is
unsurprising, because the direct CD2–CD58 interaction draws
the cell closer to the bilayer, leading to a larger repulsive force that
requires more bonds to overcome. Our values for the 2D
association constant Kb1 between the alefacept-epitope complex
and CD16b are of order 1mm2. These values are similar to
previous results for the 2D association constant between CD2 and
CD58, which range from 0.1 to 0:9mm2 [16,34,38]. Overall, our
fit parameters are largely consistent with those from the literature.
Our data are best described by a model in which the level of
immobilized CD2 on the T cell is proportional to the contact area,
rather than the degree of CD2 cross-linking. This suggests that
signaling from isolated cross-linked CD2 pairs may be less effective
than signaling from larger aggregates or from regions of high CD2
density, such as the contact region. A similar effect is seen in
signaling from the immune receptor FceRI on rat basophilic
leukemia cells, in which receptor dimers signal weakly compared
to larger aggregates [39]. Furthermore, recent experiments have
observed signaling in Jurkat T cells adhering to bilayers presenting
CD58, the natural binding partner of CD2 [40].
Our models assume immobilization is a global effect, affecting
all CD2 epitopes; we make this assumption because localized
models of immobility yield equilibrium behavior identical to the
fully mobile model, which does not fit our data. For example, a
model might assume that only receptors cross-linked by ligand are
immobilized. However, because ligand binding (and thus cross-
linking) is reversible, any cross-linked pair of receptors will
eventually break up and become mobile again. In equilibrium,
this model would thus yield identical results to allowing all
receptors to be mobile. Similarly, a model might assume that only
receptors within the contact area were immobilized, so that all
receptors outside the contact area would be free to diffuse to the
contact area. Given that immobile receptors have very similar
binding properties to mobile receptors once they reach the contact
region, such a model should also yield very similar results to the
fully mobile model.
In our system, comparing the bridging bond density b of
approximately 200mm{2 with the initial cellular CD2 density of
roughly 80mm{2, we see that the density increase in the contact
region is roughly a factor of 2.5. This increases the fraction of CD2
nearest neighbors within a given distance by the same factor of 2.5
Model of Immunoadhesin-Mediated Cell Adhesion
PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e19701(Eq. 1), similarly increasing the probability of interaction. Thus the
increased density of CD2 in the contact region may promote
interactions between CD2 molecules and drive signaling. When
alefacept adheres T cells to NK cells in vivo, FccRIIIa receptors
on the NK cell will be similarly concentrated in the contact region,
and this concentration may contribute to the signal that drives
NK-mediated killing of target cells. Moreover, we expect the
repulsive force to be greater between cells than between a cell and
a bilayer; therefore, the in vivo bridging bond density is probably
larger, leading to greater in vivo receptor concentration than seen
in our experiments.
In summary, we have developed an equilibrium model for the
immunoadhesin-mediated adhesion of cells to surfaces. Our
analysis suggests guidelines for the design of therapeutic
immunoadhesins. Furthermore, applying our model to experi-
ments on Jurkat T cells suggests that an active cellular process may
be increasing CD2 immobility in response to alefacept-mediated
surface adhesion.
Supporting Information
Figure S1 Sensitivity of our results to sR, sE, and KX. A:
As sE and sR vary from our assumed value of 0.75, the plot shows
relative changes of best-fit results for the completely mobile model
with Anon~0. Inset shows the same data on a logarithm scale.
Most results are very insensitive, but the best-fit values for Kb1 and
Kb2 do depend on sE and sR.B :A sKx varies from our assumed
value, the plot shows relative changes of best-fit results for the
completely mobile model with Anon~0. Inset shows the same data
on a logarithm scale. Most results are very insensitive, but the best-
fit value of Kb2 is inversely proportional to the assumed value of
Kx.
(EPS)
Figure S2 Illustrative model solution with divergence at
large g. Open circles show the solution for d as a function of g for
a particular set of model parameters. The solid black line is the
filtered solution, accounting for the divergence and fixing dƒ0:5.
The red line is the function g~0:13z2d, and the resulting
solution for the model in which g depends on d is shown by the red
star. The dashed green line is the fraction k of cross-linked
epitopes as a function of g, and the solid green line is the function
g~0:13zk. The resulting solution of the model in which g
depends on k is shown by the green diamond.
(EPS)
Figure S3 Model with lognormal distribution of epitope
counts. Shown is the best-fit model with all epitopes mobile.
(EPS)
Text S1 Full model details and derivations.
(PDF)
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